RU96122647A - HA FACTOR INHIBITORS - Google Patents
HA FACTOR INHIBITORSInfo
- Publication number
- RU96122647A RU96122647A RU96122647/04A RU96122647A RU96122647A RU 96122647 A RU96122647 A RU 96122647A RU 96122647/04 A RU96122647/04 A RU 96122647/04A RU 96122647 A RU96122647 A RU 96122647A RU 96122647 A RU96122647 A RU 96122647A
- Authority
- RU
- Russia
- Prior art keywords
- group
- chg
- paph
- alkyl
- palme
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 43
- 125000000217 alkyl group Chemical group 0.000 claims 40
- 229910052739 hydrogen Inorganic materials 0.000 claims 28
- 125000001424 substituent group Chemical group 0.000 claims 19
- 125000003710 aryl alkyl group Chemical group 0.000 claims 18
- 150000001413 amino acids Chemical class 0.000 claims 16
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 13
- -1 thionaphthyl Chemical group 0.000 claims 13
- 125000004404 heteroalkyl group Chemical group 0.000 claims 11
- 125000006239 protecting group Chemical group 0.000 claims 9
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 8
- 108010074860 Factor Xa Proteins 0.000 claims 7
- 229940090034 Ibu Drugs 0.000 claims 7
- 125000003277 amino group Chemical group 0.000 claims 7
- 229910052799 carbon Inorganic materials 0.000 claims 7
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 7
- 125000003118 aryl group Chemical group 0.000 claims 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 6
- PQBAWAQIRZIWIV-UHFFFAOYSA-N Methylpyridinium Chemical compound C[N+]1=CC=CC=C1 PQBAWAQIRZIWIV-UHFFFAOYSA-N 0.000 claims 5
- 125000002252 acyl group Chemical group 0.000 claims 5
- 125000003368 amide group Chemical group 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- 125000000320 amidine group Chemical group 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 125000005842 heteroatoms Chemical group 0.000 claims 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000011780 sodium chloride Substances 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000004663 dialkyl amino group Chemical group 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 2
- 102000001189 Cyclic Peptides Human genes 0.000 claims 2
- 108010069514 Cyclic Peptides Proteins 0.000 claims 2
- 240000003121 Marrubium vulgare Species 0.000 claims 2
- 150000001298 alcohols Chemical class 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- 125000001691 aryl alkyl amino group Chemical group 0.000 claims 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 239000000460 chlorine Substances 0.000 claims 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 2
- 125000004185 ester group Chemical group 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 125000001033 ether group Chemical group 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 239000011737 fluorine Substances 0.000 claims 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims 2
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine group Chemical group NC(=N)N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 125000001041 indolyl group Chemical group 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000001624 naphthyl group Chemical group 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000001749 primary amide group Chemical group 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000003156 secondary amide group Chemical group 0.000 claims 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- 239000011593 sulfur Substances 0.000 claims 2
- 125000003142 tertiary amide group Chemical group 0.000 claims 2
- 125000005207 tetraalkylammonium group Chemical group 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N Amino radical Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims 1
- 210000004369 Blood Anatomy 0.000 claims 1
- 125000005354 acylalkyl group Chemical group 0.000 claims 1
- 125000002877 alkyl aryl group Chemical group 0.000 claims 1
- 150000001409 amidines Chemical class 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 125000004429 atoms Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 125000004432 carbon atoms Chemical group C* 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 230000002255 enzymatic Effects 0.000 claims 1
- 238000005755 formation reaction Methods 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical group 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 claims 1
- 239000011630 iodine Substances 0.000 claims 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N iodine atom Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- KAESVJOAVNADME-UHFFFAOYSA-N pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 1
- 238000007363 ring formation reaction Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
Claims (1)
Х выбран из группы, состоящей из N, CH и NC(O), R1' и R1" независимо выбраны из группы, состоящей из Н, алкила, ацила, арила, арилалкила и групп, защищающих аминогруппу, и где R1 может быть замещенным; R2 означает -СR99R100, где R99 и R100 независимо выбраны из группы, включающей Н, алкил, арилалкил, гетероарилалкил и гетероарил, и где R99 и R100 независимо могут быть замещенными; R3 выбран из группы, включающей -С(О)-, -СН2-, -СНR99-С(О)- и -С(О)-NR35-СН2-С(О)-, где R35 означает СНR55 мостиковой группы -С(О)-СR55-; R4 выбран из группы, включающей -СН2- и -NR50-, где R50 выбран из группы, включающей Н, алкил, арилалкил и гетероцикл; R5 означает = СR201R202, где R201 и R202 независимо выбраны из группы, включающей Н, алкил, арил и арилалкил, и где R201 и R202 независимо могут быть замещенными; R6 означает заместитель, выбранный из группы, включающей - С(О), -СН2- и -СНR99-С(О)-; R7 выбран из группы, включающей -СН2- и -NR51, где R51 означает Н, алкил, арилалкил, гетероалкил и гетероарилалкил, и любой из этих радикалов замещен заместителем, выбранным из группы, включающей Q и (СН2)n-Q, где n = 1-5 и Q выбран из группы, включающей аминную, амидиновую, имидазольную и гуанидиновую группы, которые могут быть замещенными, и моно-, ди-, три- или тетраакиламмоний фармацевтически приемлемой соли, отличающееся тем, что изоуреид или изотиоуреид; R8 означает -СR210R211-, где R210 и R211 независимо выбраны из группы, включающей Н, алкил, алкиларил и гетероцикл, причем любой из этих радикалов может быть замещен заместителем, выбранным из группы, включающей Q и -(СН2)n-Q, где n = 1-5 и Q выбран из группы, включающей аминную, амидиновую, имидазольную и гуанидиновую группы, которые могут быть замещенными, и моно-, ди-, три- или тетраакиламмоний фармацевтически приемлемой соли, ее изоуреид или изотиоуреид; R9 выбран из группы, состоящей из -С(О)-, -СН2- и СНR99-С(О); и где, когда m=1, В выбран из группы, включающей 1-20 аминокислот, -NНR52, -NR60R61-, ОR70 и СНR60R61, где R52 выбран из группы, включающей Н, алкил, арилалкил, гетероарилалкил и гетероарил; где R60 и R61 независимо выбраны из группы, включающей Н, алкил, арилалкил, арил, гетероарилалкил, где R70 выбран из группы, состоящей из Н, алкила, арилалкила и гетероарилалкила; и где, когда m=0, В выбран из группы, включающей 1-20 аминокислот, -ОR70, -NНR52 и NR60R61, который присоединен к R6 амидной связью или сложноэфирной связью; где В может быть замещен заместителем, при условии, что когда R3 означает -СН2- или -СНR99-С(О)-, R4 означает NR50; когда R4 означает -СН2-, R3 означает -С(О)- или -СНR99-С(О)-; когда R4 означает -СН2-, R3 означает -С(О)- или -СНR99-С(О)-; когда R6 означает -СН2-, R7 означает -NНR51-; когда R7 означает -СН2-, R6 означает -С(О)- или -СНR99-С(О)-; когда R4 означает NR50 и R1 означает R50 и R1' вместе образуют мостиковую группу формулы -С(О)- СНR55-, где СНR55 является R50 и карбонильная группа является R1', и R1" и R55 независимо означают Н, С1-С6 алкил или арилалкил; и когда R3 означает -С(О)-NR35-СН2-С(О)-, тогда R4 означает -NR50-, R1 означает R35 и R1' вместе образуют мостиковую группу формулы -С(О)СНR55-, где С(О) является R1' и СНR55 является R35; и R55 независимо означают Н или С1-С6-алкил.1. A compound specifically inhibiting the activity of factor Xa having the general formula A1-A2- (A3) m -B, where m is 0 or 1; A1 is R 1 -R 2 -R 3 ; A2 means R 4 -R 5 -R 6 ; A3 means R 7 -R 8 -R 9 ; R 1 selected from the group consisting of i) 1-20 amino acids;
X is selected from the group consisting of N, CH and NC (O), R 1 'and R 1 "are independently selected from the group consisting of H, alkyl, acyl, aryl, arylalkyl and amino protecting groups, and where R 1 may be substituted; R 2 is —CR 99 R 100 , where R 99 and R 100 are independently selected from the group consisting of H, alkyl, arylalkyl, heteroarylalkyl and heteroaryl, and where R 99 and R 100 may independently be substituted; R 3 is selected from a group including —C (O) -, —CH 2 -, —CHR 99 —C (O) - and —C (O) —NR 35 —CH 2 —C (O) -, where R 35 means CHR 55 bridged the group -C (O) -CR 55 -; R 4 is selected from the group consisting of -CH 2 - and -NR 50 - wherein R 50 is selected from c ppy consisting of H, alkyl, arylalkyl, and heterocycle; R 5 is = CR 201 R 202, wherein R 201 and R 202 are independently selected from the group consisting of H, alkyl, aryl and arylalkyl, and wherein R 201 and R 202 independently can be substituted; R 6 means a substituent selected from the group consisting of —CH (O), —CH 2 - and —CHR 99 —C (O) -; R 7 is selected from the group consisting of —CH 2 - and —NR 51 , where R 51 is H, alkyl, arylalkyl, heteroalkyl and heteroarylalkyl, and any of these radicals is substituted with a substituent selected from the group consisting of Q and (CH 2 ) n -Q, where n = 1-5 and Q is selected from the group consisting of amine , amidine, them azole and the guanidine group which may be substituted, and mono-, di-, tri- or tetraakilammony pharmaceutically acceptable salt thereof, characterized in that isoureide or isothioureide; R 8 means —CR 210 R 211 -, where R 210 and R 211 are independently selected from the group consisting of H, alkyl, alkylaryl and heterocycle, wherein any of these radicals may be substituted with a substituent selected from the group consisting of Q and - (CH 2 ) n -Q, where n = 1-5 and Q is selected from the group consisting of amine, amidine, imidazole and guanidine groups, which may be substituted, and mono-, di-, tri- or tetraakylammonium of a pharmaceutically acceptable salt, its isoureid or isothioureid; R 9 is selected from the group consisting of —C (O) -, —CH 2 -, and CHR 99 —C (O); and where, when m = 1, B is selected from the group consisting of 1-20 amino acids, —NHR 52 , —NR 60 R 61 -, OR 70 and CHR 60 R 61 , where R 52 is selected from the group consisting of H, alkyl, arylalkyl, heteroarylalkyl and heteroaryl; where R 60 and R 61 are independently selected from the group consisting of H, alkyl, arylalkyl, aryl, heteroarylalkyl, where R 70 is selected from the group consisting of H, alkyl, arylalkyl and heteroarylalkyl; and where, when m = 0, B is selected from the group consisting of 1-20 amino acids, —OR 70 , —NHR 52, and NR 60 R 61 , which is attached to R 6 with an amide bond or an ester bond; where B may be substituted with a substituent, provided that when R 3 is —CH 2 - or —CHR 99 —C (O) -, R 4 is NR 50 ; when R 4 is —CH 2 -, R 3 is —C (O) - or —CHR 99 —C (O) -; when R 4 is —CH 2 -, R 3 is —C (O) - or —CHR 99 —C (O) -; when R 6 is —CH 2 -, R 7 is —NHR 51 -; when R 7 is —CH 2 -, R 6 is —C (O) - or —CHR 99 —C (O) -; when R 4 means NR 50 and R 1 means R 50 and R 1 ′ together form a bridging group of the formula —C (O) —CHR 55 -, where CHR 55 is R 50 and the carbonyl group is R 1 ′, and R 1 ″ and R 55 are independently H, C 1 —C 6 alkyl or arylalkyl; and when R 3 is —C (O) —NR 35 —CH 2 —C (O) -, then R 4 is —NR 50 -, R 1 is R 35 and R 1 ′ together form a bridging group of the formula —C (O) CHR 55 -, where C (O) is R 1 ′ and CHR 55 is R 35 ; and R 55 is independently H or C 1 -C 6 alkyl.
22. Соединение по п.17, отличающееся тем, что А1 выбран из группы, включающей Tyr, F(pNH2), mAph, pAph и Nal (2), который содержит 0 или 1 группу, защищающую аминогруппу; А2 выбран из группы, состоящей из Ile и Chg; А3 выбран из группы, включающей Arg, PalMe (3), Dab (N-C3H7N), Сар (N-C3H7N), Orn (Nδ-C3H7N); и В выбран из группы, включающей Н, ОН, NH2, от одной до пяти аминокислот или их функциональных эквивалентов и группу, защищающую карбоксильную группу.21. The compound according to p. 17, wherein A3 is selected from the group consisting of Arg, PalMe (3), Dab (NC 3 H 7 N), Dap (NC 3 H 7 N) and Orn (N δ -C 3 H 7 N).
22. The compound according to 17, characterized in that A1 is selected from the group comprising Tyr, F (pNH 2 ), mAph, pAph and Nal (2), which contains 0 or 1 group protecting the amino group; A2 is selected from the group consisting of Ile and Chg; A3 is selected from the group consisting of Arg, PalMe (3), Dab (NC 3 H 7 N), Car (NC 3 H 7 N), Orn (N δ -C 3 H 7 N); and B is selected from the group consisting of H, OH, NH 2 , from one to five amino acids or their functional equivalents, and a group protecting the carboxyl group.
Ac-pAph-Chg-PalMe(3)-NH-CH2-Chx;
Ac-pAph-Chg-PalMe(3)-NH-2CMT;
Ac-pAph-Chg-PalMe(3)-NH-Chx;
Ac-F(pNH2)-Chg-Dab(Ny-C3HN7)-L-P-NH2;
Bz-F(pNH2)-Chg-R-L-P-NH2;
Tos-F(pNH2)-Chg-R-L-P-NH2;
Ac-Y-(3-1)-Chg-R-L-P-NH2;
y-Chg-R-L-NH2;
Ac-F(pNH2)-Chg-ol;
Cyclopentyl-CO-pAph-Chg-PalMe(3)-NH2;
3-Igc-pAph-Chg-PalMe(3)-NH2;
Bzf-pAph-Chg-PalMe(3)-NH2;
3-Igc-F(pNH2)-Chg-R-L-P-NH2;
Ac-F(pNH2)-Chg-R-NH-2-thiazolyl;
2-Furoyl-pAph-Chg-PalMe(3)-NH2;
5-Me-2-thienyl-CO-pAph-Chg-PalMe(3)-NH2;
Ac-Nal(2)-Chg-R-NH-2-thiazolyl;
2-Bzf-F(pNH2)-Chg-R-L-P-NH2;
Ac-pAph-Chg-Dab(Ny-C3H7N)-L-P-NH2;
Ac-(iBu)pAph-Chg-R-L-P-NH2;
Ac-pAph-Chg-R-Gla-P-NH2;
Ac-pAph-Chg-R-Pen(CH2COOH)-P-NH2;
Ac-pAph-Chg-R-L-P-NH2;
Ac-F(pNH2)-Chg-R-(Me)L-P-NH2;
Ac-F(pNH2)-Chg-R-OEt;
Ac-F(pNH2)-Chg-Orn(N6C3H7N)-L-P-NH2;
Ac-F(pNH2)-Chg-R-L-P-NH2;
Ac-Nal(2)-Chg-R-L-P-NH2;
Ac-pAph-Chg-Dab(Ny-C3H7N)-NH2;
Ac-pAph-Chg-PalMe(3)-NH2;
Ac-pAph-Chg-PalMe(3)-L-P-NH2;
Ac-pAph-Chg-R-NH2;
Ac-pAph-Chg-R-OH;
Ac-pAph-Chg-R-ol;
DIPA-(m)pAph-Chg-R-L-P-NH2;
DIPA-(m)F(pNH2)-Chg-R-L-P-NH2;
Isn-F(pNH2)-Chg-R-L-P-NH2;
Pza-F(pNH2)-Chg-R-L-P-NH2;
Tfa-(iBu)Y-Chg-R-L-P-NH2; и
Tfa-(iBu)Y-I-Orn(N6C3H7N)-L-P-NH2.23. The compound according to item 22, selected from the group including:
Ac-pAph-Chg-PalMe (3) -NH-CH 2 -Chx;
Ac-pAph-Chg-PalMe (3) -NH-2CMT;
Ac-pAph-Chg-PalMe (3) -NH-Chx;
Ac-F (pNH 2 ) -Chg-Dab (Ny-C 3 HN 7 ) -LP-NH 2 ;
Bz-F (pNH 2 ) -Chg-RLP-NH 2 ;
Tos-F (pNH 2 ) -Chg-RLP-NH 2 ;
Ac-Y- (3-1) -Chg-RLP-NH 2 ;
y-Chg-RL-NH 2 ;
Ac-F (pNH 2 ) -Chg-ol;
Cyclopentyl-CO-pAph-Chg-PalMe (3) -NH 2 ;
3-Igc-pAph-Chg-PalMe (3) -NH 2 ;
Bzf-pAph-Chg-PalMe (3) -NH 2 ;
3-Igc-F (pNH 2 ) -Chg-RLP-NH 2 ;
Ac-F (pNH 2 ) -Chg-R-NH-2-thiazolyl;
2-Furoyl-pAph-Chg-PalMe (3) -NH 2 ;
5-Me-2-thienyl-CO-pAph-Chg-PalMe (3) -NH 2 ;
Ac-Nal (2) -Chg-R-NH-2-thiazolyl;
2-Bzf-F (pNH 2 ) -Chg-RLP-NH 2 ;
Ac-pAph-Chg-Dab (Ny-C 3 H 7 N) -LP-NH 2 ;
Ac- (iBu) pAph-Chg-RLP-NH 2 ;
Ac-pAph-Chg-R-Gla-P-NH 2 ;
Ac-pAph-Chg-R-Pen (CH 2 COOH) -P-NH 2 ;
Ac-pAph-Chg-RLP-NH 2 ;
Ac-F (pNH 2 ) -Chg-R- (Me) LP-NH 2 ;
Ac-F (pNH 2 ) -Chg-R-OEt;
Ac-F (pNH 2 ) -Chg-Orn (N 6 C 3 H 7 N) -LP-NH 2 ;
Ac-F (pNH 2 ) -Chg-RLP-NH 2 ;
Ac-Nal (2) -Chg-RLP-NH 2 ;
Ac-pAph-Chg-Dab (Ny-C 3 H 7 N) -NH 2 ;
Ac-pAph-Chg-PalMe (3) -NH 2 ;
Ac-pAph-Chg-PalMe (3) -LP-NH 2 ;
Ac-pAph-Chg-R-NH 2 ;
Ac-pAph-Chg-R-OH;
Ac-pAph-Chg-R-ol;
DIPA- (m) pAph-Chg-RLP-NH 2 ;
DIPA- (m) F (pNH 2 ) -Chg-RLP-NH 2 ;
Isn-F (pNH 2 ) -Chg-RLP-NH 2 ;
Pza-F (pNH 2 ) -Chg-RLP-NH 2 ;
Tfa- (iBu) Y-Chg-RLP-NH 2 ; and
Tfa- (iBu) YI-Orn (N 6 C 3 H 7 N) -LP-NH 2 .
Ac-pAph-Chg-PalMe(3)-NH-CH2-Chx;
Ac-pAph-Chg-PalMe(3)-NH2;
Bzf-pAph-Chg-PalMe(3)-NH2;
Ac-pAph-Chg-PalMe(3)-L-P-NH2;
Ac-pAph-Chg-PalMe(3)-NH2;
Cyclopentyl-CO-pAph-Chg-PalMe(3)-NH2;
3-Icg-pAph-Chg-PalMe(3)-NH2;
2-Furoyl-pAph-Chg-PalMe(3)-NH2;
5-Me-thienyl-CO-pAph-Chg-PalMe(3)-NH2; и
Ac-pAph-Chg-PalMe(3)-ol.24. The compound according to item 22, selected from the group including:
Ac-pAph-Chg-PalMe (3) -NH-CH 2 -Chx;
Ac-pAph-Chg-PalMe (3) -NH 2 ;
Bzf-pAph-Chg-PalMe (3) -NH 2 ;
Ac-pAph-Chg-PalMe (3) -LP-NH 2 ;
Ac-pAph-Chg-PalMe (3) -NH 2 ;
Cyclopentyl-CO-pAph-Chg-PalMe (3) -NH 2 ;
3-Icg-pAph-Chg-PalMe (3) -NH 2 ;
2-Furoyl-pAph-Chg-PalMe (3) -NH 2 ;
5-Me-thienyl-CO-pAph-Chg-PalMe (3) -NH 2 ; and
Ac-pAph-Chg-PalMe (3) -ol.
(4-(N-метилпиридиний))метил;
2(3-(N-метилпиридиний))эт-1-ил;
1-(4-(N-метилпиридиний))эт-1-ил;
(n-амидин)бензил;
2-(4-(N-метилпиридиний))проп-2-ил; и
2-(4-(N-метилпиридиний))эт-1-ил.27. The compound according to p. 26, wherein the heteroalkyl is selected from the group including:
(4- (N-methylpyridinium)) methyl;
2 (3- (N-methylpyridinium)) et-1-yl;
1- (4- (N-methylpyridinium)) et-1-yl;
(n-amidine) benzyl;
2- (4- (N-methylpyridinium)) prop-2-yl; and
2- (4- (N-methylpyridinium)) et-1-yl.
Ac-Tyr-Ile-Arg-Leu-Ala-NH2;
Ac-Tyr-Ile-Arg-Leu-NH2;
Ac-(iBu)-Tyr-Ile-Arg-Leu-Pro-NH2;
Ac-Tyr-Ile-Arg-N(CH3)O(CH3);
Ac-Tyr-{Y(CH2NH)}-ILe-Arg-Leu-Pro-NH2;
Ac-Tyr-Ile-Arg-NH-CH2(4-Pyridyl);
Ac-Tyr-Ile-{Y(CH2NH)}-Arg-Leu-Pro-NH2;
Ac-Tyr-Chg-Arg(NO2)-{Y-CH2NH)}-Leu-NH2;
Ac-Tyr-Ile-Arg-{Y(COCH2)}Gly-Pro-NH2;
Ac-Tyr-Ile-Dab(Ny-C3H7N)-Leu-Ala-NH2;
Ac-Tyr-Ile-PalMe(3)-NH2;
Tyr-Ile-Arg-NH2;
D-Tyr-Ile-Arg-Leu-Pro-NH2;
Ac-(Bzl)Gly-(Chx)Gly-(3-guanidopropyl)Gly-NH2;
Cyclo(Gly-Tyr-Ile-Arg-Gly);
Tfa-(iBu)Tyr-Chg-Arg-Leu-Pro-NH2;
Ac-pAph-Chg-Arg-Leu-Pro-NH2;
Ac-Nal(2)-Chg+Arg-Leu-Pro-NH2;
Sc-pAph-Chg-PalMe-NH2,
и их фармацевтически приемлемые соли, амиды, эфиры, спирты и альдегиды.35. The compound according to clause 29, selected from the group including:
Ac-Tyr-Ile-Arg-Leu-Ala-NH 2 ;
Ac-Tyr-Ile-Arg-Leu-NH 2 ;
Ac- (iBu) -Tyr-Ile-Arg-Leu-Pro-NH 2 ;
Ac-Tyr-Ile-Arg-N (CH 3 ) O (CH 3 );
Ac-Tyr- {Y (CH 2 NH)} - ILe-Arg-Leu-Pro-NH 2 ;
Ac-Tyr-Ile-Arg-NH-CH 2 (4-Pyridyl);
Ac-Tyr-Ile- {Y (CH 2 NH)} - Arg-Leu-Pro-NH 2 ;
Ac-Tyr-Chg-Arg (NO 2 ) - {Y-CH 2 NH)} - Leu-NH 2 ;
Ac-Tyr-Ile-Arg- {Y (COCH 2 )} Gly-Pro-NH 2 ;
Ac-Tyr-Ile-Dab (Ny-C 3 H 7 N) -Leu-Ala-NH 2 ;
Ac-Tyr-Ile-PalMe (3) -NH 2 ;
Tyr-Ile-Arg-NH 2 ;
D-Tyr-Ile-Arg-Leu-Pro-NH 2 ;
Ac- (Bzl) Gly- (Chx) Gly- (3-guanidopropyl) Gly-NH 2 ;
Cyclo (Gly-Tyr-Ile-Arg-Gly);
Tfa- (iBu) Tyr-Chg-Arg-Leu-Pro-NH 2 ;
Ac-pAph-Chg-Arg-Leu-Pro-NH 2 ;
Ac-Nal (2) -Chg + Arg-Leu-Pro-NH 2 ;
Sc-pAph-Chg-PalMe-NH 2 ,
and their pharmaceutically acceptable salts, amides, esters, alcohols and aldehydes.
R3 означает -С(О)-;
R4 означает -NН-;
R5 означает -CНR201-, где R201 является алкилом;
R6 означает -С(О)-;
R7 означает -NН-;
R8 означает -CНR210-, где R210 является гетероалкилом,
имеющим, по меньшей мере, один формальный положительный заряд, где гетероатомом является азот; R9 означает -С(О)-; и В выбран из группы, включающей -ORb и -N-RcRd, где Rb выбран из группы, состоящей из Н, алкила и группы, защищающей карбоксигруппу, Rc выбран из группы, включающей Н и алкил, и Rd выбран из группы, включающей алкил, гетероалкил и 1-20 аминокислот, которые могут быть замещены заместителем, и где С-концевая группа может быть модифицирована группой, защищающей карбоксигруппу, группой первичного амида или частью циклического пептида в качестве вторичной или третичной амидной группы, образовавшейся с аминогруппой радикала R1 или восстановлением до спирта.37. The method according to clause 36, wherein using the compound according to claim 1, where R 1 means selected from the group consisting of H, —COR a , —SO 2 —R a , an amino protecting group, 1-6 amino acids which may be substituted, and wherein the N-terminal group of said 1-6 amino acids is substituted with a substituent selected from the group including H, —CO — R a , —SO 2 —R a and an amino protecting group; and where R a is selected from the group consisting of alkyl, aryl and heteroalkyl; selected from the group consisting of H, acyl and alkyl; X is N; R 2 means —CHR 99 -, where R 99 is selected from the group consisting of alkyl, aryl, arylalkyl, heteroalkyl and heteroaryl, which may be substituted with a substituent selected from the group consisting of 1-6 fluorine, chlorine, bromine, iodine atoms, 1 -6 amino groups, nitro groups, amidine groups, amido groups, carboxy groups, ester groups, ether groups and hydroxyl groups;
R 3 means —C (O) -;
R 4 is —NH—;
R 5 means —CHR 201 -, where R 201 is alkyl;
R 6 means —C (O) -;
R 7 is —NH—;
R 8 means —CHR 210 -, where R 210 is heteroalkyl,
having at least one formal positive charge, wherein the heteroatom is nitrogen; R 9 means —C (O) -; and B is selected from the group consisting of —OR b and —NR c R d , where R b is selected from the group consisting of H, alkyl and a carboxy protecting group, R c is selected from the group consisting of H and alkyl, and R d is selected from the group consisting of alkyl, heteroalkyl and 1-20 amino acids which may be substituted by a substituent, and where the C-terminal group may be modified by a carboxy protecting group, a primary amide group or part of a cyclic peptide as a secondary or tertiary amide group formed with an amino radical R 1 or by reduction to sleep ta.
Ac-pAph-Chg-PalMe(3)-NH-CH2-Chx;
Ac-pAph-Chg-PalMe(3)-NH-Chx;
Bzf-pAph-Chg-PalMe(3)-NН2;
Ac-pAph-Chg-PalMe(3)-L-P-NН2;
Ac-pAph-Chg-PalMe(3)-NН2;
Cyclopentyl-CO-pAph-Chg-PalMe(3)-NH2;
3-Igc-pAph-Chg-PalMe(3)-NH2;
2-Furoyl-pAph-Chg-PalMe(3)-NH2;
5-Me-2-thienyl-CO-pAph-Chg-PalMe(3)-NH2; и
Ac-pAph-Chg-PalMe(3)-ol.39. The method according to § 39, wherein the specified compound is selected from the group including:
Ac-pAph-Chg-PalMe (3) -NH-CH 2 -Chx;
Ac-pAph-Chg-PalMe (3) -NH-Chx;
Bzf-pAph-Chg-PalMe (3) -NH 2 ;
Ac-pAph-Chg-PalMe (3) -LP-NH 2 ;
Ac-pAph-Chg-PalMe (3) -NH 2 ;
Cyclopentyl-CO-pAph-Chg-PalMe (3) -NH 2 ;
3-Igc-pAph-Chg-PalMe (3) -NH 2 ;
2-Furoyl-pAph-Chg-PalMe (3) -NH 2 ;
5-Me-2-thienyl-CO-pAph-Chg-PalMe (3) -NH 2 ; and
Ac-pAph-Chg-PalMe (3) -ol.
Ac-Y-R-L-A-NH2;
Ac-Y-R-L-P-NH2;
Ac-(iBu)Y-I-R-L-P-NH2;
Ac-Y-I-R-N(CH3)O(CH3);
Ac-Y-{Y(CH2NH)}-I-R-L-P-NH2;
Ac-Y-I-R-NH-CH2(4-Pyridyl);
Ac-Y-I-{Y(CH2NH)}-R-L-P-NH2;
Ac-Y-Chg-R(NO2){Y(CH2NH)}-L-NH2;
Ac-Y-I-R-{Y-COCH2)}-G-P-NH2;
Ac-Y-I-Dab(Ny-C3H7N)-L-A-NH2;
Ac-Y-I-PalMe(3)-NH2;
y-I-R-NH2;
D-Y-R-L-P-NH2;
Ac-(Bzl)Gly-(Chx)Gly-(3-guanidoropyl)Gly-NH2;
Cyclo(G-Y-I-R-G);
Tfa-(iBu)Y-Chg-R-L-P-NH2;
Ac-pAph-Chg-R-L-P-NH2;
Ac-Nal(2)-Chg-R-L-P-NH2;
и их фармацевтически приемлемые соли, амиды, эфиры, спирты альдегиды.40. The method according to § 38, characterized in that the said compound is selected from the group including:
Ac-YRLA-NH 2 ;
Ac-YRLP-NH 2 ;
Ac- (iBu) YIRLP-NH 2 ;
Ac-YIRN (CH 3 ) O (CH 3 );
Ac-Y- {Y (CH 2 NH)} - IRLP-NH 2 ;
Ac-YIR-NH-CH 2 (4-Pyridyl);
Ac-YI- {Y (CH 2 NH)} - RLP-NH 2 ;
Ac-Y-Chg-R (NO 2 ) {Y (CH 2 NH)} - L-NH 2 ;
Ac-YIR- {Y-COCH 2 )} - GP-NH 2 ;
Ac-YI-Dab (Ny-C 3 H 7 N) -LA-NH 2 ;
Ac-YI-PalMe (3) -NH 2 ;
yIR-NH 2 ;
DYRLP-NH 2 ;
Ac- (Bzl) Gly- (Chx) Gly- (3-guanidoropyl) Gly-NH 2 ;
Cyclo (GYIRG);
Tfa- (iBu) Y-Chg-RLP-NH 2 ;
Ac-pAph-Chg-RLP-NH 2 ;
Ac-Nal (2) -Chg-RLP-NH 2 ;
and their pharmaceutically acceptable salts, amides, esters, alcohols, aldehydes.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23305494A | 1994-04-26 | 1994-04-26 | |
US08/233,054 | 1994-04-26 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU96122647A true RU96122647A (en) | 1999-01-27 |
RU2152954C1 RU2152954C1 (en) | 2000-07-20 |
Family
ID=22875692
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU96122647/04A RU2152954C1 (en) | 1994-04-26 | 1995-04-25 | Inhibitors of xa factor |
Country Status (27)
Country | Link |
---|---|
EP (2) | EP0758341B1 (en) |
JP (1) | JP3655632B2 (en) |
KR (1) | KR100380124B1 (en) |
CN (1) | CN1181091C (en) |
AT (1) | ATE262536T1 (en) |
AU (1) | AU707653B2 (en) |
CA (1) | CA2186497C (en) |
CZ (1) | CZ296439B6 (en) |
DE (1) | DE69532754T2 (en) |
DK (1) | DK0758341T3 (en) |
EE (1) | EE03973B1 (en) |
ES (1) | ES2214500T3 (en) |
FI (1) | FI120494B (en) |
HU (1) | HUT76346A (en) |
IL (1) | IL113505A (en) |
LT (1) | LT4218B (en) |
LV (1) | LV11740B (en) |
NO (1) | NO318759B1 (en) |
NZ (1) | NZ284977A (en) |
PL (1) | PL188132B1 (en) |
PT (1) | PT758341E (en) |
RU (1) | RU2152954C1 (en) |
SI (1) | SI9520044B (en) |
SK (1) | SK286094B6 (en) |
TW (1) | TW409129B (en) |
WO (1) | WO1995029189A1 (en) |
ZA (1) | ZA953361B (en) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL321759A1 (en) * | 1995-02-17 | 1997-12-22 | Basf Ag | Novel thrombosin inhibitors |
US6069130A (en) * | 1995-06-07 | 2000-05-30 | Cor Therapeutics, Inc. | Ketoheterocyclic inhibitors of factor Xa |
US5747458A (en) * | 1995-06-07 | 1998-05-05 | Chiron Corporation | Urokinase receptor ligands |
TR199801107T2 (en) * | 1995-12-20 | 1998-10-21 | Hoechst Marion Roussel Inc. | N-Acetyl (L)-4-cyanophenylalanine Ac (L)-phe (4-CN)-OH and N-Acetyl-(L)-p-amidinophenylalanine-cyclohexyl-glycine-�-(3-N-methylpyridinium)- A new process for the preparation of alanine Ac-(L)-pAph-Chg-PalMe (3)-NH2. |
US5766932A (en) * | 1995-12-20 | 1998-06-16 | Hoechst Marion Roussel, Inc. | Process for preparing N-acetyl(L)-4-cyanophenylalanine from a mixture of the corresponding D,L ethyl esters using subtilisin |
US6194435B1 (en) | 1996-10-11 | 2001-02-27 | Cor Therapeutics, Inc. | Lactams as selective factor Xa inhibitors |
US6369080B2 (en) | 1996-10-11 | 2002-04-09 | Cor Therapeutics, Inc. | Selective factor Xa inhibitors |
US6063794A (en) | 1996-10-11 | 2000-05-16 | Cor Therapeutics Inc. | Selective factor Xa inhibitors |
US6262047B1 (en) | 1996-10-11 | 2001-07-17 | Cor Therapeutics, Inc. | Selective factor Xa inhibitors |
WO1998046627A1 (en) | 1997-04-14 | 1998-10-22 | Cor Therapeutics, Inc. | SELECTIVE FACTOR Xa INHIBITORS |
WO1998046628A1 (en) * | 1997-04-14 | 1998-10-22 | Cor Therapeutics, Inc. | SELECTIVE FACTOR Xa INHIBITORS |
CA2285685A1 (en) | 1997-04-14 | 1998-10-22 | Cor Therapeutics, Inc. | Selective factor xa inhibitors |
US7109326B2 (en) | 1997-04-15 | 2006-09-19 | Genentech, Inc. | Halo-alkoxycarbonyl prodrugs |
US6228854B1 (en) | 1997-08-11 | 2001-05-08 | Cor Therapeutics, Inc. | Selective factor Xa inhibitors |
US6218382B1 (en) | 1997-08-11 | 2001-04-17 | Cor Therapeutics, Inc | Selective factor Xa inhibitors |
US6333321B1 (en) | 1997-08-11 | 2001-12-25 | Cor Therapeutics, Inc. | Selective factor Xa inhibitors |
GB9727123D0 (en) * | 1997-12-22 | 1998-02-25 | Int Centre Genetic Eng & Bio | Synthesis of diamines |
AU743881B2 (en) | 1997-12-24 | 2002-02-07 | Sanofi-Aventis Deutschland Gmbh | Indole derivatives as inhibitors or factor Xa |
EP0987274A1 (en) * | 1998-09-15 | 2000-03-22 | Hoechst Marion Roussel Deutschland GmbH | Factor VIIa Inhibitors |
EP1016663A1 (en) * | 1999-01-02 | 2000-07-05 | Aventis Pharma Deutschland GmbH | Novel malonic acid derivatives, processes for their preparation, their use and pharmaceutical compositions containing them (inhibition of factor Xa activity) |
WO2000040571A1 (en) * | 1999-01-02 | 2000-07-13 | Aventis Pharma Deutschland Gmbh | Novel malonic acid derivatives, processes for their preparation, their use and pharmaceutical compositions containing them (inhibition of factor xa activity) |
EP1022268A1 (en) * | 1999-01-02 | 2000-07-26 | Aventis Pharma Deutschland GmbH | Arylalkanoyl derivatives, processes for their preparation, their use and pharmaceutical compositions containing them |
AU2285700A (en) | 1999-01-02 | 2000-07-24 | Aventis Pharma Deutschland Gmbh | Arylalkanoyl derivatives, processes for their preparation, their use and pharmaceutical compositions containing them |
EP1059302A1 (en) * | 1999-06-08 | 2000-12-13 | Aventis Pharma Deutschland GmbH | Factor VIIa inhibitors |
EP1095933A1 (en) | 1999-10-30 | 2001-05-02 | Aventis Pharma Deutschland GmbH | Novel N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them |
JP5088598B2 (en) * | 1999-12-14 | 2012-12-05 | 昭和電工株式会社 | Process for producing salts of cyanobenzylamines |
WO2001044171A1 (en) | 1999-12-14 | 2001-06-21 | Showa Denko K. K. | Process for producing salt of cyanobenzylamine or derivative |
ATE325810T1 (en) * | 2000-01-28 | 2006-06-15 | Sanofi Aventis Deutschland | METHOD FOR PRODUCING ACETYLAMIDINIOPHENYLALANYL-CYCLOHEXYLGLYCYL-PYRIDYLALANINAMIDES |
EP1127884A1 (en) * | 2000-02-26 | 2001-08-29 | Aventis Pharma Deutschland GmbH | Novel malonic acid derivatives, processes for their preparation, their use as inhibitor of factor XA activity and pharmaceutical compositions containing them |
DE10029015A1 (en) | 2000-06-15 | 2001-12-20 | Curacyte Ag | Coagulation Factor Xa inhibitor, useful for treatment, prophylaxis or diagnosis of thromboembolic disease, comprising acylated 3- or 4-amidino-benzylamine derivative |
DE60126143T2 (en) | 2000-12-06 | 2007-11-15 | Sanofi-Aventis Deutschland Gmbh | GUANIDINE AND AMIDINE COMPOUNDS, AND THEIR USE AS FACTOR XA INHIBITORS |
EP1314733A1 (en) | 2001-11-22 | 2003-05-28 | Aventis Pharma Deutschland GmbH | Indole-2-carboxamides as factor Xa inhibitors |
ATE399175T1 (en) | 2002-03-11 | 2008-07-15 | Curacyte Ag | UROKINASE INHIBITORS, THEIR PRODUCTION AND USE |
HUE025683T2 (en) | 2002-12-03 | 2016-04-28 | Pharmacyclics Llc | 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors |
US7358268B2 (en) | 2002-12-04 | 2008-04-15 | Sanofi-Aventis Deutschland Gmbh | Imidazole derivatives as factor Xa inhibitors |
US7429581B2 (en) | 2002-12-23 | 2008-09-30 | Sanofi-Aventis Deutschland Gmbh | Pyrazole-derivatives as factor Xa inhibitors |
DE10301300B4 (en) | 2003-01-15 | 2009-07-16 | Curacyte Chemistry Gmbh | Use of acylated 4-amidino- and 4-guanidinobenzylamines for the inhibition of plasma kallikrein |
EP1479677A1 (en) | 2003-05-19 | 2004-11-24 | Aventis Pharma Deutschland GmbH | New indole derivatives as factor xa inhibitors |
US7223780B2 (en) | 2003-05-19 | 2007-05-29 | Sanofi-Aventis Deutschland Gmbh | Triazole-derivatives as blood clotting enzyme factor Xa inhibitors |
US7317027B2 (en) | 2003-05-19 | 2008-01-08 | Sanofi-Aventis Deutschland Gmbh | Azaindole-derivatives as factor Xa inhibitors |
EP1479680A1 (en) | 2003-05-19 | 2004-11-24 | Aventis Pharma Deutschland GmbH | Azaindole derivatives as Factor Xa inhibitors |
EP1479675A1 (en) | 2003-05-19 | 2004-11-24 | Aventis Pharma Deutschland GmbH | Indazole-derivatives as factor Xa inhibitors |
US7741341B2 (en) | 2003-05-19 | 2010-06-22 | Sanofi-Aventis Deutschland Gmbh | Benzimidazole-derivatives as factor Xa inhibitors |
DE10342108A1 (en) | 2003-09-11 | 2005-04-14 | Curacyte Chemistry Gmbh | Basic substituted benzylamine analogs as coagulation factor Xa inhibitors, their preparation and use |
EP1568698A1 (en) | 2004-02-27 | 2005-08-31 | Aventis Pharma Deutschland GmbH | Pyrrole-derivatives as factor Xa inhibitors |
US7446210B2 (en) | 2004-10-26 | 2008-11-04 | Janssen Pharmaceutica N.V. | Factor Xa compounds |
EP1724269A1 (en) | 2005-05-20 | 2006-11-22 | Sanofi-Aventis Deutschland GmbH | Heteroaryl-carboxylic acid (sulfamoyl alkyl) amide - derivatives as factor Xa inhibitors |
DE102005044319A1 (en) | 2005-09-16 | 2007-03-22 | Curacyte Chemistry Gmbh | 2- (Aminomethyl) -5-chloro-benzylamide derivatives and their use as inhibitors of coagulation factor Xa |
DE102006050672A1 (en) | 2006-10-24 | 2008-04-30 | Curacyte Discovery Gmbh | New glycylglycine derivatives with a benzylsulfonylamido group and an amidino-organylamido group at the opposite chain ends, used in drugs for reducing loss of blood, e.g. in operations |
EP1918718A1 (en) * | 2006-10-31 | 2008-05-07 | Roche Diagnostics GmbH | Methods and devices for electrochemical determination of factor Xa inhibitors in blood samples |
BRPI0809655B8 (en) | 2007-04-13 | 2021-05-25 | Millennium Pharm Inc | use of a compound and a therapeutic agent, pharmaceutical composition, and kit |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4275153A (en) * | 1978-08-03 | 1981-06-23 | American Hospital Supply Corporation | Analytical fluorogenic substrates for proteolytic enzymes |
CA1161431A (en) * | 1979-05-11 | 1984-01-31 | Lars G. Svendsen | Tripeptide derivatives |
US4469679A (en) * | 1983-02-16 | 1984-09-04 | Smithkline Beckman Corporation | Octapeptide vasopressin antagonists |
HU191961B (en) * | 1984-08-02 | 1987-04-28 | Richter Gedeon Vegyeszet | Process for producing 1,5 and 8 substituted peptides of angiotenzin-ii antagonistic activity |
EP0627929B1 (en) * | 1992-02-14 | 1998-09-30 | Corvas International, Inc. | Inhibitors of thrombosis |
-
1995
- 1995-04-25 WO PCT/US1995/005268 patent/WO1995029189A1/en active IP Right Grant
- 1995-04-25 ZA ZA953361A patent/ZA953361B/en unknown
- 1995-04-25 CZ CZ0314096A patent/CZ296439B6/en not_active IP Right Cessation
- 1995-04-25 HU HU9602954A patent/HUT76346A/en not_active Application Discontinuation
- 1995-04-25 ES ES95917736T patent/ES2214500T3/en not_active Expired - Lifetime
- 1995-04-25 AU AU23683/95A patent/AU707653B2/en not_active Ceased
- 1995-04-25 PT PT95917736T patent/PT758341E/en unknown
- 1995-04-25 DK DK95917736T patent/DK0758341T3/en active
- 1995-04-25 JP JP52785395A patent/JP3655632B2/en not_active Expired - Fee Related
- 1995-04-25 CA CA002186497A patent/CA2186497C/en not_active Expired - Fee Related
- 1995-04-25 EE EE9600146A patent/EE03973B1/en not_active IP Right Cessation
- 1995-04-25 SI SI9520044A patent/SI9520044B/en not_active IP Right Cessation
- 1995-04-25 KR KR1019960706004A patent/KR100380124B1/en not_active IP Right Cessation
- 1995-04-25 EP EP95917736A patent/EP0758341B1/en not_active Expired - Lifetime
- 1995-04-25 DE DE69532754T patent/DE69532754T2/en not_active Expired - Lifetime
- 1995-04-25 AT AT95917736T patent/ATE262536T1/en not_active IP Right Cessation
- 1995-04-25 RU RU96122647/04A patent/RU2152954C1/en not_active IP Right Cessation
- 1995-04-25 CN CNB951928112A patent/CN1181091C/en not_active Expired - Fee Related
- 1995-04-25 SK SK1366-96A patent/SK286094B6/en not_active IP Right Cessation
- 1995-04-25 NZ NZ284977A patent/NZ284977A/en not_active IP Right Cessation
- 1995-04-25 EP EP03021617A patent/EP1384725A3/en not_active Withdrawn
- 1995-04-26 IL IL11350595A patent/IL113505A/en not_active IP Right Cessation
- 1995-05-11 TW TW084104681A patent/TW409129B/en active
-
1996
- 1996-09-25 PL PL95317067A patent/PL188132B1/en not_active IP Right Cessation
- 1996-10-25 FI FI964317A patent/FI120494B/en not_active IP Right Cessation
- 1996-10-25 LT LT96-151A patent/LT4218B/en not_active IP Right Cessation
- 1996-10-25 NO NO19964553A patent/NO318759B1/en not_active IP Right Cessation
- 1996-11-15 LV LVP-96-410A patent/LV11740B/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU96122647A (en) | HA FACTOR INHIBITORS | |
AU622419B2 (en) | Inhibitors of non-enzymatic cross-linking | |
EA200200619A1 (en) | NEPEPTIDILE INHIBITORS OF VLA-4-DEPENDENT CELL ASSOCIATION USED IN THE TREATMENT OF INFLAMMATORY, AUTOIMUM AND RESPIRATORY DISEASES | |
KR890002209A (en) | Methylene phosphonoalkylphosphinate, pharmaceutical compositions containing the same, and methods of treating abnormal calcium and phosphate metabolism | |
KR900014424A (en) | Amino acid derivatives | |
KR940003939A (en) | Imidazolidine derivatives | |
PT92497B (en) | PROCESS FOR THE PREPARATION OF UREIA DERIVATIVES OF ENZYME INHIBITING DIPEPTIDEES, AND OF PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
KR890000494A (en) | Staurosporin derivative substituted on methylamino nitrogen | |
KR960705786A (en) | Substituted 5-ring heterocycles, their preparation and their use | |
KR960041192A (en) | Dipeptide Promotes Release of Growth Hormone | |
HUP0104364A2 (en) | Pyrrolidine derivatives-ccr-3 receptor antagonists | |
NO953093L (en) | Compounds with both strong calcium antagonist and antioxidant activity, and use thereof as cell protective agents | |
PT97357B (en) | PROCESS FOR THE PREPARATION OF POLY-ISOBUTILENE ADHESIVES FOR TRANSDERMIC DEVICES | |
KR890005148A (en) | N-acylamino acid derivatives and uses thereof | |
BR9814499B1 (en) | SYNTHETIC OPIOID PEPTIDE OR PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME, AND PHARMACEUTICAL COMPOSITION | |
RU98117075A (en) | PROTEASE INHIBITORS SERINE | |
RU97122265A (en) | ANTAGONISTS OF THE VITRONECTIN RECEPTOR, THEIR RECEIVING AND APPLICATION | |
RU97109847A (en) | DERIVATIVES OF AMINOTHETRAZOLE, USEFUL AS A NITROGEN OXIDE SYNTHASE INHIBITORS | |
BG94282A (en) | 2,9-DISUBSTITUTED-4H-PYRIDO/1,2,-A/PYRIMIDIN-4-ONES | |
US4310517A (en) | Tumor-resolving and histolytic medicaments and their use | |
RU2002120462A (en) | Substituted derivatives of N-benzylindol-3-yl-glyoxylic acid with antitumor activity (options), their acid additive salts and their use (options), pharmaceutical preparation, dosage form | |
EP0327919A2 (en) | Method and agents for preventing staining of teeth | |
US20020061878A1 (en) | Diazacycloalkanedione derivatives | |
TR199801218T2 (en) | N-acyl-2-substituted-4-(Benzimidazolyl-or imidazopyridinyl-substituted residues)-piperidines as tachykinin antagonists. | |
EP1485345A2 (en) | Urokinase inhibitors, production and use thereof |